Deep Venous Thrombosis in a Preterm Newborn of a Mother with Activated Protein C Resistance

Abstract

Get full access to this article

View all access options for this article.

References

1. Dahlback B . Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995;85:607-614.

2. Nowak-Gottl U , Koch HG , Aschka I , et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. BrJHaematol. 1996;92:992-998.

3. Dahlback B , Carlson M , Svensson RJ . Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1009.

4. Bertina RM , Koeleman PBC , Koster T , et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.

5. Kalafatis M , Bertina RM , Rand MD , Mann KG . Characterization of the molecular defect in FV R506Q. J Biol Chem. 1995;270:4053-4057.

6. Svensson PJ , Dahlback B . Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-521.

7. Kodish E , Potter C , Kirschbaum NE , Foster PA . Activated protein C resistance in a neonate with venous throm bosis.J Pediatr. 1995;127:645-649.

8. GreengardJS , Eichinger S , GriffinJH , Bauer KA . Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg Gin mutation in the gene for factor V. NEnglJ Med. 1994;331:1159-1159.

9. Brenner B , Zivelin A , Lanir N , et al. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood. 1996;88:877-880.

10.

10. Greengard JS , Eichenger S , Griffin JH , Bauer KA . Brief report: thrombosis among homozygous siblings with resistance to activated protein C due to an Arg to Gln mutation in the gene for factor V. N Engl J Med. 1994; 331:1559-1562.

11.

11. Gandrille S , Greengard JS , AlhencGelas M , et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood. 1995;86:219-224.

12.

12. Koeleman BPC , Reitsma PH , Allaart CF , Bertina RM . Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood. 1994;84:1031-1036.

13.

13. Andrew M , Paes B , Johnston M . Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12:95-104.

14.

14. Dahlback B . Physiological anticoagulation: resistance to activated protein C and venous thromboembolism. J Clin Invest. 1994;94:923-927.

15.

15. Zoller B , Svensson PJ , He X , Dahlback B . Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.

16.

16. Dulitzki M , Pauzner R , Langevitz P , et al. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol. 1996;87:380-383.